文献速递认知障碍与痴呆

临床诊断与脑脊液谱不一致患者中的白质异常与认知

White matter abnormalities and cognition in patients with conflicting diagnoses and CSF profiles.
PubMed 文献 · Neurology · 2018-03-23

研究纳入阿尔茨海默病神经影像学倡议数据库中236名临床诊断为认知正常老年人、轻度认知障碍和阿尔茨海默病的个体,先用支持向量机评估各生物标志物对临床诊断的分类效用,再用一般线性模型分析脑脊液β-淀粉样蛋白1-42、磷酸化tau181p及MRI白质信号异常体积与认知下降的关系。结果显示白质信号异常在脑脊液生物标志物水平不典型者中对记忆和执行功能下降具有额外预测价值。

要点

  • 白质信号异常体积在全部236人中显著贡献于执行和记忆域认知下降的预测。
  • 脑脊液双阳性者中,白质信号异常仅显著贡献于未来执行功能下降的模型。
  • 脑脊液水平不典型者中,白质信号异常是执行功能下降的唯一显著预测因子。

核心结论

  • 白质信号异常对老年人认知进展具有额外预测力,在认知受损但不符合阿尔茨海默病预期脑脊液生物标志物谱的个体中作为生物标志物最有效。

研究设计与样本

  • 研究纳入阿尔茨海默病神经影像学倡议数据库中236名临床诊断为认知正常老年人、轻度认知障碍和阿尔茨海默病的个体。
  • 先以支持向量机实验确定各生物标志物对临床诊断分类的效用,再以一般线性模型评估脑脊液β-淀粉样蛋白1-42、磷酸化tau181p及MRI白质信号异常体积与认知下降的关系。
  • 分析在全部患者中及按脑脊液指标临床切点定义的亚组内进行。

主要发现

  • 脑脊液生物标志物单独区分阿尔茨海默病与认知正常老年人的准确率为82%,加入白质信号异常未提升该准确率。
  • 在全部236人中,脑脊液生物标志物和白质信号异常体积均显著贡献于执行和记忆域认知下降的预测。
  • 在脑脊液两项生物标志物均达病理水平的个体中,白质信号异常仅显著贡献于未来执行功能下降的模型。
  • 在脑脊液生物标志物水平不典型(与认知正常老年人相似)的个体中,白质信号异常显著贡献于记忆下降的预测,且是执行功能下降的唯一显著预测因子。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether white matter changes influence progression of cognitive decline in individuals with clinically diagnosed Alzheimer disease (AD) and differing biomarker profiles. METHODS: Two hundred thirty-six individuals from the Alzheimer's Disease Neuroimaging Initiative database with clinical diagnoses of cognitively normal older adult (older controls [OCs]), mild cognitive impairment, and AD were studied. Support vector machine experiments were first performed to determine the utility of various biomarkers for classifying individuals by clinical diagnosis. General linear models were implemented to assess the relationships between CSF measures of β-amyloid 1-42, phosphorylated tau181p, and MRI-based white matter signal abnormality (WMSA) volumes and cognitive decline. Analyses were performed across all patients as well as within subgroups of individuals that were defined by clinical cutoff points for both CSF measures. RESULTS: CSF biomarkers alone classified individuals with AD vs OCs with 82% accuracy, and the addition of WMSA did not enhance this. Both CSF biomarkers as well as WMSA volume significantly contributed to predicting cognitive decline in executive and memory domains when assessed across all 236 individuals. In individuals with pathologic levels of both CSF biomarkers, WMSA only significantly contributed to models of future executive function decline. In individuals with subpathologic CSF biomarker levels (levels similar to those in OC individuals), WMSA significantly contributed to prediction of memory decline and were the sole significant predictor of executive function decline. CONCLUSIONS: WMSA hold additional predictive power regarding cognitive progression in older individuals and are most effective as biomarkers in individuals who are cognitively impaired but do not fit the expected CSF biomarker profile of AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lindemer ER, Greve DN, Fischl B, et al. White matter abnormalities and cognition in patients with conflicting diagnoses and CSF profiles. Neurology. 2018. PMID: 29572277. doi:10.1212/WNL.0000000000005353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。